These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26283687)

  • 21. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.
    Andersen LB; Fountain JW; Gutmann DH; Tarlé SA; Glover TW; Dracopoli NC; Housman DE; Collins FS
    Nat Genet; 1993 Feb; 3(2):118-21. PubMed ID: 8499944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
    Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
    Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.
    Cichowski K; Santiago S; Jardim M; Johnson BW; Jacks T
    Genes Dev; 2003 Feb; 17(4):449-54. PubMed ID: 12600938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural and biochemical consequences of NF1 associated nontruncating mutations in the Sec14-PH module of neurofibromin.
    Welti S; Kühn S; D'Angelo I; Brügger B; Kaufmann D; Scheffzek K
    Hum Mutat; 2011 Feb; 32(2):191-7. PubMed ID: 21089070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).
    Upadhyaya M; Kluwe L; Spurlock G; Monem B; Majounie E; Mantripragada K; Ruggieri M; Chuzhanova N; Evans DG; Ferner R; Thomas N; Guha A; Mautner V
    Hum Mutat; 2008 Jan; 29(1):74-82. PubMed ID: 17960768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
    Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
    Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel neurofibromin (NF1) interaction with the leucine-rich pentatricopeptide repeat motif-containing protein links neurofibromatosis type 1 and the French Canadian variant of Leigh's syndrome in a common molecular complex.
    Arun V; Wiley JC; Kaur H; Kaplan DR; Guha A
    J Neurosci Res; 2013 Apr; 91(4):494-505. PubMed ID: 23361976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.
    Wallace MD; Pfefferle AD; Shen L; McNairn AJ; Cerami EG; Fallon BL; Rinaldi VD; Southard TL; Perou CM; Schimenti JC
    Genetics; 2012 Oct; 192(2):385-96. PubMed ID: 22851646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity.
    Corral T; Jiménez M; Hernández-Muñoz I; Pérez de Castro I; Pellicer A
    J Cell Physiol; 2003 Nov; 197(2):214-24. PubMed ID: 14502561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
    Kumar R; Angelini S; Hemminki K
    Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos.
    Kuorilehto T; Nissinen M; Koivunen J; Benson MD; Peltonen J
    J Bone Miner Res; 2004 Jun; 19(6):983-9. PubMed ID: 15125795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.